Novo Nordisk Wins EU Clearance for Haemophilia Drug as FDA Adds Eye-Risk Warnings to GLP-1 Labels
Published on 11/15/2026 at 14:41 | Editorial boerse-global.de
Novo Nordisk closed Friday's session up 2.7%, a move media reports linked to European approval of its haemophilia therapy FREHEMGO rather than to a separate US regulatory development that same day. The FDA on 9 November requested new label warnings for GLP-1 medicines including Ozempic and Wegovy, covering a possible elevated risk of NAION, a rare eye condition that can cause permanent vision loss. The Associated Press also covered the vision-loss warning. Neither report pointed to the safety notice as the driver of the share price gain.
The European Commission granted marketing authorisation for FREHEMGO, whose active ingredient is denecimig, on Friday. It is indicated for routine prevention or reduction of bleeding episodes in adults and children with haemophilia A, with or without inhibitors. Novo Nordisk intends to bring the product to its first European markets next year, with dosing available on a monthly, fortnightly or weekly schedule.
Sickle Cell Filings and Fresh CagriSema Data
Friday brought a second regulatory milestone: Novo Nordisk submitted applications for Etavopivat to both the FDA and the EMA. The once-daily investigational treatment for sickle cell disease targets adolescents and adults, and the filings rest on results from the Phase 3 HIBISCUS trial. The company expects regulatory decisions in 2027.
A day earlier, Novo Nordisk published Phase 3 results for its investigational CagriSema from the REDEFINE 9 study. The data were presented at ObesityWeek and appeared in The Lancet Diabetes & Endocrinology.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Guidance Lifted, Targets Raised, Rating Unchanged
Novo Nordisk raised its full-year outlook on 4 November alongside results for the first nine months of 2026, lifting guidance for both adjusted sales and adjusted operating profit. For 2026 the company now projects currency-adjusted growth of between -2% and +2% in each of those two measures.
Third-quarter 2026 adjusted operating profit climbed 27% in currency-adjusted terms to DKK 31.7 billion, according to the company's regulatory announcement.
Deutsche Bank responded the same day by lifting its price target to DKK 240 from DKK 225, according to media reports. The house kept its sell recommendation, so the higher target did not come with an improved rating.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
Buyback and a Long-Run Diabetes Pledge
In its 9 November statement, Novo Nordisk put repurchases under the current programme at roughly 27.8 million B shares through 6 November, at a cost of about DKK 8.01 billion.
The company also committed USD 200 million to the World Diabetes Foundation on Wednesday. The funding runs from 2027 to 2036 and is aimed at diabetes prevention and care in low- and middle-income countries, covering both efforts to head off the disease and treatment for those already living with it.
Ad
Novo Nordisk Stock: New Analysis - 15 November
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
